Study of EBI-005 in Dry Eye Disease (DED)

Summary

This is a randomized, double masked study designed to evaluate the safety of EBI-005 5 mg/mL topical ophthalmic solution given three times daily (TID) compared to vehicle-control over a one year period in subjects with dry eye disease (DED). Approximately 188 subjects will be enrolled to either EBI-005 or vehicle at up to 15 centers in the United States (US) and Canada.

Timeline

Start

2015-04

Primary completion

2016-06

Completion

2016-07

Drugs

Indications